106401-68-7

Basic information

• Product Name: Doxorubicin IMpurity B
• Synonyms: Doxorubicin IMpurity B;(8S,10S)-10-[(3-AMino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-(2-broMo-1,1-diMethoxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-Methoxy-5,12-naphthacenedione (Doxorubicin IMpurity);(8S,10S)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-8-(2-bromo-1,1-dimethoxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;Doxorubicin Hydrochloride impurity B
• CAS NO: 106401-68-7
• Molecular Formula: C₂₉H₃₄BrNO₁₁
• Molecular Weight: 652.48436
• EINECS: 204-888-2
• Product Categories: Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 106401-68-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 804.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.63±0.1 g/cm3(Predicted)
• PKA: 7.51±0.60(Predicted)
• CAS DataBase Reference: Doxorubicin IMpurity B(CAS DataBase Reference)
• NIST Chemistry Reference: Doxorubicin IMpurity B(106401-68-7)
• EPA Substance Registry System: Doxorubicin IMpurity B(106401-68-7)

Safety Data

• Hazardous Substances Data: 106401-68-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 106401-68-7 differently. You can refer to the following data:
1. (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-(2-bromo-1,1-dimethoxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione, is the metabolite of Doxorubicin (D558000), which is a neoplasm inhibitor
2. Doxorubicin Ketal Derivative is an impurity and a derivative compound of Doxorubicin. An antibacterial.

Upstream product

• 23541-50-6 daunomycin hydrochloride 
• 122-51-0 orthoformic acid triethyl ester 
• 149-73-5 trimethyl orthoformate 
• 67-56-1 methanol 

Downstream Products

• 56124-62-0 valrubicin 
• 65026-79-1 14-bromodaunorubicin 
• 596124-23-1 C₅₁H₆₀BrNO₂₂ 

Relevant articles and documents

Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell)

Improvement in the therapeutic index of doxorubicin, a cytotoxic molecule, has been sought through its chemical conjugation to short (15-23 amino acid) peptide sequences called Vectocell peptides. Vectocell peptides are highly charged drug delivery peptides and display a number of characteristics that make them attractive candidates to minimize many of the limitations observed for a broad range of cytotoxic molecules. The studies reported here characterized the in vitro and in vivo efficacy of a range of Vectocell peptides conjugated to doxorubicin through different linkers. These studies show that the in vivo therapeutic index of doxorubicin can be improved by conjugation with a specific Vectocell peptide (DPV 1047) through an ester linker to C14 of doxorubicin, in both colon and breast tumor models. This conjugate was also shown to have significant in vivo antitumoral activity in a model resistant to doxorubicin, suggesting that this conjugate is able to circumvent the multidrug resistance (MDR) phenotype. These experiments therefore provide support for the use of the Vectocell technology with other cytotoxic agents.

Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicin

A general scheme of synthesis of antibiotic doxorubicin derivatives is based on the 13-dimethyl ketal of 14-bromodaunorubicin (4). The interaction of 4 with melibiose (5), lactose (6), 3-methoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-4- oxybenz